Assessment of the potential of pathological stains in human prostate cancer

Journal of Clinical and Diagnostic Research

Volumn 8, Issue 1, 2014, Pages 124-128

  Khanna, Anchit ^a   Patil, Rani ^b   Deshmukh, Abhay ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b DATTA MEGHE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Alcian blue; Argyrophilic Nucleolar Organiser Region (AgNOR); Benign Prostatic Hyperplasia (BPH); Prostate Cancer

Indexed keywords

ALCIAN BLUE; EOSIN; HEMATOXYLIN; MUCIN;

ADULT; AGE; AGED; ARTICLE; CHROMOSOME NOR; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORPHOMETRICS; OUTCOME ASSESSMENT; PATHOLOGY; PERIODIC ACID SCHIFF STAIN; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; STAINING; VERY ELDERLY;

EID: 84892745050     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2014/7002.3938     Document Type: Article

References (36)

1. Boehm JS, Hession MT, Bulmer SE, Hahn WC. Transformation of human and murine fibroblasts without viral oncoproteins. Mol Cell Biol. 2005; 25 (15): 6464-74. PubMed PMID: 16024784. Pubmed Central PMCID: 1190359. Epub 2005/07/19.
2. Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, et al. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One. 2011; 6 (3): e17979. PubMed PMID: 21445343. Pubmed Central PMCID: 3062549. Epub 2011/03/30.
3. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. 2009; 101 (11): 793-805. PubMed PMID: 19470954. Epub 2009/05/28.
4. Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemela M, et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov. 2013; 3 (2): 182-97. PubMed PMID: 23306062. Pubmed Central PMCID: 3572190. Epub 2013/01/12.
5. Mathiasen DP, Egebjerg C, Andersen SH, Rafn B, Puustinen P, Khanna A, et al. Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene. 2012; 31 (3): 390-401. PubMed PMID: 21706057. Epub 2011/06/28.
6. Khanna A. Regulation of Cancerous inhibitor of PP2A (CIP2A) by small molecule inhibitor for c-Jun NH2-Terminal Kinases (JNKs), SP600125, in Human Fibrosarcoma (HT1080) cells. F1000Research. 2013; 2013 (2): 174. Epub 14 AUGUST 2013.
7. Khanna A, Böckelman C, Laine A, Ristimäki A, Visakorpi T, Westermarck J. 859 Constitutive DNA-damage signaling promotes cancer cell proliferation through Chk1-CIP2A pathway. Ejc Supplements. 2010; 8 (5): 217-217.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144 (5): 646-74. PubMed PMID: 21376230. Epub 2011/03/08.
9. Finkel T, Serrano M, Blasco MA. The common biology of cancer and ageing. Nature. 2007 16; 448 (7155): 767-74. PubMed PMID: 17700693. Epub 2007/08/19.
10. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev. 2000 1; 14 (19): 2410-34. PubMed PMID: 11018010. Epub 2000/10/06.
11. Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 1985; 45 (8): 3663-7. PubMed PMID: 2410099. Epub 1985/08/01.
12. Brewster SF, Oxley JD, Trivella M, Abbott CD, Gillatt DA. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol. 1999; 161 (4): 1238-43. PubMed PMID: 10081877. Epub 1999/03/19.
13. Sherwood ER, Berg LA, Mitchell NJ, McNeal JE, Kozlowski JM, Lee C. Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. J Urol. 1990; 143 (1): 167-71. PubMed PMID: 1688457. Epub 1990/01/01.
14. Bui M, Reiter RE. Stem cell genes in androgen-independent prostate cancer. Cancer Metastasis Rev. 1998; 17 (4): 391-9. PubMed PMID: 10453283. Epub 1999/08/24.
15. Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008 Jun 10; 26 (17): 2862-70. PubMed PMID: 18539965.
16. Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol. 2008r; 179 (4): 1235-42. PubMed PMID: 18280514. Pubmed Central PMCID: 2667246. Epub 2008/02/19.
17. Canil CM, Tannock IF. Should bisphosphonates be used routinely in patients with prostate cancer metastatic to bone? J Natl Cancer Inst. 2002; 94 (19): 1422-3. PubMed PMID: 12359844. Epub 2002/10/03.
18. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst. 2002; 94 (1): 17-25. PubMed PMID: 11773278. Epub 2002/01/05.
19. Bissell MJ, Le Beyec J, Anderson RL. Prostate cancer in bone: importance of context for inhibition of matrix metalloproteinases. J Natl Cancer Inst. 2002; 94 (1): 4-5. PubMed PMID: 11773268. Pubmed Central PMCID: 3027556. Epub 2002/01/05.
20. Khurd P, Bahlmann C, Maday P, Kamen A, Gibbs-Strauss S, Genega EM, et al. Computer-Aided Gleason Grading of Prostate Cancer Histopathological Images Using Texton Forests. Proc IEEE Int Symp Biomed Imaging. 2010; 636-9. PubMed PMID: 21221421. Pubmed Central PMCID: 3017375. Epub 2011/01/12.
21. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974; 111 (1): 58-64. PubMed PMID: 4813554. Epub 1974/01/01.
22. Gaeta JF, Englander LC, Murphy GP. Comparative evaluation of National Prostatic Cancer Treatment Group and Gleason systems for pathologic grading of primary prostatic cancer. Urology. 1986; 27 (4): 306-8. PubMed PMID: 3962053. Epub 1986/04/01.
23. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3. 0 ng/ml or lower. JAMA. 2005; 294 (1): 66-70. PubMed PMID: 15998892. Epub 2005/07/07.
24. Presti JC, Jr., Hovey R, Carroll PR, Shinohara K. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate. J Urol. 1996; 156 (5): 1685-90. PubMed PMID: 8863571. Epub 1996/11/01.
25. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009; 9 (12): 874-85. PubMed PMID: 19935676. Pubmed Central PMCID: 2951677. Epub 2009/11/26.
26. Mathur SK, Gupta S, Marwah N, Narula A, Singh S, Arora B. Significance of mucin stain in differentiating benign and malignant lesions of prostate. Indian J Pathol Microbiol. 2003; 46 (4): 593-5. PubMed PMID: 15025351. Epub 2004/03/18.
27. Crocker J, Boldy DA, Egan MJ. How should we count AgNORS? Proposals for a standardized approach. J Pathol. 1989; 158 (3): 185-8. PubMed PMID: 2475599. Epub 1989/07/01.
28. Grignon DJ, O'Malley FP. Mucinous metaplasia in the prostate gland. Am J Surg Pathol. 1993; 17 (3): 287-90. PubMed PMID: 7679558. Epub 1993/03/01.
29. Mathur SK, Gupta S, Marwah N, Narula A, Singh S, Arora B. Significance of mucin stain in differentiating benign and malignant lesions of prostate. Indian journal of pathology & microbiology. 2003; 46 (4): 593-5. PubMed PMID: 15025351. Epub 2004/03/18.
30. Franks LM, O'Shea JD, Thomson AE. Mucin in the Prostate: A Histochemical Study in Normal Glands, Latent, Clinical, and Colloid Cancers. Cancer. 1964; 17: 983-91. PubMed PMID: 14202599. Epub 1964/08/01.
31. Hukill PB, Vidone RA. Histochemistry of mucus and other polysaccharides in tumors. II. Carcinoma of the prostate. Lab Invest. 1967; 16 (3): 395-406. PubMed PMID: 4225797. Epub 1967/03/01.
32. Lloyd SN, Johnson CP, Brown IL, Kirk D. Nucleolar organizer regions in benign and malignant prostatic disease. Histopathology. 1991; 18 (5): 449-52. PubMed PMID: 1715842. Epub 1991/05/01.
33. Deschenes J, Weidner N. Nucleolar organizer regions (NOR) in hyperplastic and neoplastic prostate disease. Am J Surg Pathol. 1990; 14 (12): 1148-55. PubMed PMID: 2252105. Epub 1990/12/01.
34. Contractor H, Ruschoff J, Hanisch T, Ulshofer B, Neumann K, Schultze-Seemann W, et al. Silver-stained structures in prostatic carcinoma: evaluation of diagnostic and prognostic relevance by automated image analysis. Urol Int. 1991; 46 (1): 9-14. PubMed PMID: 1708924. Epub 1991/01/01.
35. Kawase N, Shiokawa A, Ota H, Saitoh T, Yoshida H, Kazama K. Nucleolar organizer regions and PCNA expression in prostatic cancers. Pathol Int. 1994; 44 (3): 213-22. PubMed PMID: 7517763. Epub 1994/03/01.
36. Nakae S, Nakamura T, Ikegawa R, Yoshioka H, Shirono J, Tabuchi Y. Evaluation of argyrophilic nucleolar organizer region and proliferating cell nuclear antigen in colorectal cancer. J Surg Oncol. 1998; 69 (1): 28-35. PubMed PMID: 9762888. Epub 1998/10/08.